Nuheara Past Earnings Performance

Past criteria checks 0/6

Nuheara's earnings have been declining at an average annual rate of -11.8%, while the Tech industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 4.3% per year.

Key information

-11.8%

Earnings growth rate

13.0%

EPS growth rate

Tech Industry Growth	11.8%
Revenue growth rate	4.3%
Return on equity	-246.9%
Net Margin	-653.3%
Last Earnings Update	30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Nuheara makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CHIA:NUH Revenue, expenses and earnings (AUD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 23	2	-13	7	4
31 Mar 23	2	-13	8	5
31 Dec 22	2	-14	8	6
30 Sep 22	3	-14	10	6
30 Jun 22	4	-15	11	6
31 Mar 22	5	-15	11	7
31 Dec 21	7	-14	11	7
30 Sep 21	9	-11	11	7
30 Jun 21	11	-8	10	6
31 Mar 21	9	-7	11	3
31 Dec 20	7	-7	11	2
30 Sep 20	5	-9	11	3
30 Jun 20	2	-12	11	3
31 Mar 20	2	-12	11	3
31 Dec 19	2	-12	11	3
30 Sep 19	2	-11	11	2
30 Jun 19	2	-10	11	2
31 Mar 19	3	-9	11	1
31 Dec 18	3	-7	10	0
30 Sep 18	4	-7	9	0
30 Jun 18	4	-7	9	0
31 Mar 18	4	-7	8	0
31 Dec 17	4	-7	7	1
30 Sep 17	3	-6	6	0
30 Jun 17	2	-5	4	0
31 Dec 16	0	-8	2	1
30 Sep 16	0	-8	2	1
30 Jun 16	0	-7	1	1

Quality Earnings: NUH is currently unprofitable.

Growing Profit Margin: NUH is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NUH is unprofitable, and losses have increased over the past 5 years at a rate of 11.8% per year.

Accelerating Growth: Unable to compare NUH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUH is unprofitable, making it difficult to compare its past year earnings growth to the Tech industry (6.4%).

Return on Equity

High ROE: NUH has a negative Return on Equity (-246.93%), as it is currently unprofitable.

Nuheara Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Full year 2023 earnings released: AU$0.074 loss per share (vs AU$0.16 loss in FY 2022)

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

New minor risk - Share price stability

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

Full year 2023 earnings released: AU$0.074 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies